Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


News

UCL alumna awarded Professional Achievement Award by British Council

Tina Liu (UCL Centre for Transport Studies, 2010) has been announced as the winner of this year’s Professional Achievement Award in the Education UK Alumni Awards for China run by the British Council. More...

Could this UCL alumnus be the next Mark Zuckerberg?

Julia Pimentel interviews Ricardo Mighty, UCL Alumnus and founder of PinU More...

UCL Advances Director Timothy Barnes recognised for contribution to supporting entrepreneurs in Maserati 100 list

Director of UCL Advances Timothy Barnes has been included on the Maserati 100 list in recognition of his contribution to supporting the next generation of budding entrepreneurs and growing small businesses. The list was prepared by the independent Centre for Entrepreneurs in partnership with the Sunday Times. More...

UCL start-up BaseStone secures contract with the Costain Skanska Joint Venture following successful trials

BaseStone – a London-based software firm started by UCL MSc Technology Entrepreneurship graduate Alex Siljanovski – has secured a long term contract with construction Costain Skanska Joint Venture (CSJV) following trials on their Paddington site that revealed large cost savings through the use of its technology. More...

Ipsen Enters into Option Agreement to Acquire Canbex Therapeutics

Ipsen (Euronext: IPN; ADR: IPSEY) and Canbex Therapeutics Ltd (Canbex) today announced that Canbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS), known as VSN16R. Canbex is a spin-off of University College London (UCL) that raised a Series A financing of GBP 2.3 million in 2013 from MS Ventures (the corporate venture arm of Merck Serono, Merck KGaA), the Wellcome Trust and UCL Business Plc (UCLB). More...

Search UCL News